Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Vitrolife, Audiocast, Q1'26

By Inderes4/23/2026, 8:00 AM
Vitrolife

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Bronwyn Brophy O’Connor
00:01 - 12:38

Good morning, everyone, and welcome to the Vitrolife AB Group Q1 2026 Earnings Call. Thank you for dialing in. I'm joined by Pär Ihrskog, the CFO of Vitrolife AB (publ). And I'd like to start this morning and today's presentation by providing you with an update on the latest dynamics that we are seeing in the reproductive health market. I've broken this down into three key areas markets or regions, customers and competitors. So let's start with the markets. What we're seeing is European IVF cycles are remaining stable. We see cycle growth rates starting to increase in North America after a slow start to the year. And what I would point out is we're starting to see an increased seasonality there, whereby January is a particularly slow month and the growth tends to accelerate as the calendar year progresses. Middle East IVF cycle activity is significantly down as one would reasonably expect given the geopolitical situation in the Middle East. The markets are performing stronger than expected, but I would like to point out that Q1 2025 was exceptionally low. And then the other dynamic that we are seeing is an increase in regulation of genetic testing. We welcome this as we believe it's in the best interests of patients. The Vitrolife AB group has a lot of competence in the area of regulatory affairs and market access in general. I'll now move over to discuss the customers. Consolidation is continuing with chains expanding their footprint in all regions. We see an insourcing of genetic services in the Middle East. This is not surprising, given the drop in IVF cycles that I have mentioned, and clinics increasingly looking for sources of revenue. We're also seeing an increase in RFP or tenders from clinic chains. This tends to favor the full portfolio larger players. So again, we see this as an advantage for the Vitrolife AB group. And then finally demand for automation is high and it's increasing as clinics strive to improve their efficiency. Of course, this is one of the core pillars of the Vitrolife AB group's strategy to help clinics with automation. Okay, moving on then to competitors, in the market, there have been supply issues from competitors in parts of the Consumables portfolio in particular. And we have taken advantage of this dynamic capturing share. Interestingly, we're seeing an increased presence of low cost generic competitors in low price regions. I think this is going to be an interesting one to watch because regulatory demands are going up. And I think grabbing share at low prices is going to be tough to maintain as the regulatory demands increase. We, as you know, at the Vitrolife AB group have a goal of driving sustainable, profitable growth. So we will not be engaging in low-price competitive tactics. And then I think this is an interesting one to point out. Competitive activity is regionally based, despite the fact that on paper we face global players in terms of the competitive landscape. The Vitrolife AB Group is a true global player, as evidenced from our regional revenue split. However, we don't face the same competitors across the key markets. All right. We'll now move on, and I'll take you through some of the key highlights. America sales. So America sales increased by 11%. And the strategic investments that we have made in North America are clearly paying off. We're starting to see this quarter after quarter now. And if anything, the growth in North America is accelerating. We're happy to see our gross margin back up at 59.9%. In fact, this is one of our strongest gross margin performances in a long time. We are becoming more sophisticated in terms of our ability to leverage the full portfolio in the key markets, where we have decided to double down, and consumable sales increased by 9%. It was difficult to pick either Consumables or Technologies because Technologies also had a very strong performance in the quarter, but I think this Consumables number clearly demonstrates that we are improving our competitive position globally. The Technologies growth. By the way, for those of you who haven't seen the number yet, is plus 11%, as I said, organic growth in local currencies. All right. Let's now move into the regions. And we will start with our largest region, which is EMEA, accounting for 38% of the global revenue of the Vitrolife AB group. Sales of 312 million SEK in the quarter, a decline of 1% in local currencies. We had robust growth in Europe, offset by declines in cycle volumes in the Middle East. This is not lost share; it's cycle volumes. And Europe performing well. Sales of Consumables were flat. The Middle East is impacting the region's performance as a whole. Sales in Technologies decreased by 2%, with very strong sales in Europe for both capital and consumables, offset by a significant decline in capital sales in the Middle East. Would like to point out here that Europe is our most penetrated region for EmbryoScope, but clinics need for automation is driving demand. And I think what's particularly pleasing about the Technologies numbers is the Consumables revenue per EmbryoScope is accelerating nicely. Sales in Genetics decreased by 2% due again to the situation in the Middle East. And of course in this region, this is actually the region most impacted by the exit of certain tests in the Genetic Services portfolio. But I would say broadly across the region, strong performance in Europe, offset by decline in IVF cycles in the Middle East due to the situation there. Okay, let's move on now and we will take a look at market region Americas. So as you all know, we made a strategic decision to invest in sales and marketing in North America, but particularly in the United States. And we are now delivering strong double-digit growth in the largest IVF market in the world in terms of revenue. Sales of 264 million SEK and an organic growth in local currencies of 11%. What is particularly encouraging about the performance here is that it's strong across the entire portfolio. It's everywhere and well above the market growth rates. Sales in Consumables increased by 16%, and this is driven by share gains in high volume centers. This has been one of the key growth drivers for us. And in an area where we have very much doubled down and brought in specialist talent to work with us. In the large clinic chains, sales in Technologies grew by 107% as we increased adoption of EmbryoScope, and sales in Genetics increased by 2%, with a strong performance in North America, offset by a decline in low-priced markets in South America. So to conclude, very strong performance in Americas, driven by North America and, on this occasion, particularly by the United States. Okay, finally we move to APAC. So the APAC market, as you well know, has been turbulent for several quarters. So we are pleased to see some signs of recovery. We delivered sales of 232 million SEK in the quarter, an organic growth of 7%. I should also point out, as you can see here from the donut, that APAC now accounts for 29% in terms of share of revenue, higher market growth than we've seen for several quarters, partially due to a low Q1 in 2025. Consumables grew by 15% with the strong performance across the portfolio in key markets. So what we're really starting to see now is that our ability to leverage the strong position that we have in media and other areas is serving us very well in terms of our ability to start accelerating growth across the other parts of the consumables portfolio. Technology sales increased by 5% as we increased our EmbryoScope penetration, and in Genetics, sales declined by 6%. And this is primarily due to the timing of genomic kits orders from major clinic chains. This can have big swings from one quarter to the next, but to conclude overall, pleased to see APAC back in growth terms. All right. I'm going to move on to my final slide before I hand you over to Pär. As you know, we have a mission to be the leading global partner in reproductive health, striving for better outcomes for patients. Of course, we are executing on our quarterly plans, but very importantly, we need to stay on track in terms of executing on our long-term strategy. Helping us to become that leading global partner. And I'd like to give you an update in terms of how we are doing in relation to growth, innovation, and operational excellence. So when it comes to growth, we're driving profitable growth through improved market and customer segmentation. We've become much more sophisticated, strategic, and I would say premeditated, in terms of which markets we're going to play in and which markets we're not going to play in. And the same goes for customers. And this is all in the name of driving profitable growth. We're gaining share by leveraging the full Vitrolife AB Group portfolio. We are a true end-to-end provider for large clinic chains. We have Consumables, we have Technologies, and of course we have a full service in terms of Genetics. And then we are accelerating penetration of our EmbryoScope and lab controlled solutions in clinic chains. And as I mentioned in my opening slide, demand for automation to improve clinic efficiency is high and it's only increasing. In terms of innovation, we have a strong pipeline of new products, of new tests and solutions that we are going to be bringing to market in the coming quarters, and we're very excited about this. Innovation is an area where we decided to double down over the past two and a half years. We're also advancing the efficiency of the IVF clinic workflow through the use of AI and our Ida score software in embryo selection. And then when it comes to operational excellence, we're investing in IT and digital capabilities. As we've mentioned several times, this is to improve the customer journey, but also to improve connectivity with the large clinic chains. And this is where we're winning. You can see this from the results. The results of that connectivity piece are very important. And then we are taking actions to optimize our cost base across operations and back office. And of course, you're very familiar with the restructuring program that we announced in December. So with that, I'm going to hand you over to Pär to take you through the financial highlights.

Pär Ihrskog
12:39 - 18:24

Thank you Bronwyn. So some numbers, our net sales ended up at 807 million SEK. It's a -4% growth heavily impacted by negative currency, as we have seen now for four quarters in a row. I will come back to that in the next slide. Our gross margin ended up at 483 million with a gross margin of 59.9%, which is one of the stronger we've seen for many quarters. And our EBITDA ended up at 251 million and a margin of 31.1%. The increase in margin was driven by product and market mix. Strong growth in Consumables and strong growth in Technologies and strong growth in APAC. That's what I mean with the product and market mix. So, go back to the net sales, then. We ended up at 807 million SEK. We had a 5% positive organic growth in local currencies. However, the situation that started 12 months ago continues to affect us. So a negative impact from currency of 9% on the top line, ending up in a net growth of minus four. So on the gross margin, 59.9%. It's one of the strongest quarters in gross margin due to a strategic focus on key markets and product groups. We had strong sales in Technologies and Consumables, two product groups with high gross margin, and also very strong sales in APAC with high gross margin. So this is behind the product and market mix comment. If you look at the segment, Bronwyn already talked about the sales, but if we look at the gross income and gross margin, we see an improved gross margin in all regions. Very, very positive: 56.1% in Americas, compared to 53.7%; 61.7% in EMEA, compared to 59.5%; and 61.7% versus 58.4% last year. So, strong improvement. Good improvement in all regions in Gross Margin; on the Market contribution, we saw 25.9 versus 25.3 in Americas, 38.8 versus 39.2 in EMEA, and 43.4 compared to 42.4 in APAC. So all in all, we had a slight improvement in Market contribution total, 35.9% versus 35.6% last year, Quarter One. If we then look at the operational expense development over the last five quarters, we see a reduction versus the last three quarters, and it is flat compared to Q1 last year. And I will come back with some details on that. The restructuring program that Bronwyn mentioned is on track. We don't have that much impact in Q1 when it comes to savings. And the savings will kick in starting Q2. And also Q3. So on the details of OpEx, it's flat compared to Q1 last year, but we see an increase in selling and marketing that's related to the investment we've done in Americas. Bronwyn explained. We also have a slight increase in admin that is related to IT spending. And then the increase in R&D of 6 million compared to Q1 last year is related to spending that has been allocated to support upcoming product releases and launches. So the increase from these three has been offset by a positive currency revaluation effect that is booked in other income expense. So all in all, it's flat compared to last year. Then on the cash flow we usually comment upon the middle bar here. The cash flow from operating activities ended up at 172 million SEK, compared to 69 million SEK last year. Of that cash, we have invested 44 million in the ongoing investment in the new production facilities in Gothenburg, but also R&D investment in product development. And then, of the remaining cash, we have reduced our loans by 66 million, resulting in a cash flow for the period of 61 million SEK. And then to summarize the key financials, 807 million SEK, representing a 5% organic growth in local currencies. Strong gross margin of 59.9%. Strong EBITDA margin 31.1%. And our net income 101 million SEK in line with last year. Earnings per share 0.74 and our cash flow 172 million SEK versus 69 million last year. And our net debt to EBITDA of 0.6, a slight improvement from last year. And then our proposed dividend is one krona and 10 öre per share. By that, we open up for Q&A.

Operator
18:29 - 18:54

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. Please start by asking one question, followed by a follow-up question. It's then fine to queue up again for more questions. The next question comes from Ulrich Trattner from NB Carnegie. Please go ahead.

Ulrich Trattner
18:56 - 19:55

Thank you very much. And good morning, Bronwyn. And my question would relate to the growth in North America and strong development that we have seen there. And it looks like you continue to grab market share and you talk about it, but is it possible to quantify how much of the growth here is coming from normalized market versus market share gains? And especially also if we can get some nuances from whom you're grabbing this market share. My impression is that both Irvine and Kitasato are relatively aggressive in their marketing in the region. Would you say that the share is broad-based from all your competitors, or is it from a single source? And as a follow-up, how important is your Denver facility in order to grab market share versus your competitors that are predominantly outside of the US in production?

Bronwyn Brophy O’Connor
19:57 - 23:22

Okay. I think that's three questions in one, but I'm more than happy to answer them all. Ulrich. Actually, I'm going to start with the final part. So we do have a facility in Denver, as you rightly point out. We have manufacturing, but we also have our R&D and our main lab there. As you know, we also have a laboratory in Miami and customer service there. And then we have manufacturing in San Diego. So we have a strong footprint, as would be expected, and regarding who we are taking share from? It's always very difficult to say because in the IVF market, unfortunately, unlike other areas of health care, like orthopedics or cardiology, you don't have independently published data confirming the competitive position of each of the players. But equally, we report Americas together, but I can tell you, if we look at our North America growth broken out, it is significantly above cycle growth in the region. There's a lot of distraction factor going on in the market. Ulrich, the largest competitor has its own challenges with the strategic review, and that plays to our advantage. And then you have players three, four, and five consolidating into a new company. So, what I say to the team is don't get distracted, keep our heads down. We have a fantastic end-to-end, high-quality portfolio. We've invested in the region in a really, really strong team. Don't get distracted, keep your eyes on the prize and drive share gains. I think the other thing that's really helped us is that we are targeting the large clinic chains. And, they are demanding high quality, but they're also increasingly looking for automation. So, the combination of EmbryoScope and the efficiency it brings results in us seeing EmbryoScope up 107%. It's not insignificant. But the combination of EmbryoScope, then the high-quality consumables portfolio. And then, we're one of the market leaders when it comes to Genetic Services. So we're really leveraging the full, the full portfolio. And, you know, this is a guesstimate, but I think it's broad share gain from multiple players, but the distraction factor of course helps. So I've answered the manufacturing footprint. I've answered the share. And hopefully I've answered that it is well above the market growth rates without divulging the exact percentage. We don't obviously give you the breakdown. We obviously don't give you the breakdown. You see it by Genetics, by Consumables, and by Technologies. But what I can tell you is it is across the entire portfolio. It's everywhere, which is really nice and a healthy thing to see.

Ulrich Trattner
23:23 - 23:37

Okay, great. Thank you very much, Brian. Just a quick follow up. As you mentioned, more consolidation and higher tender activity. Is that something that is purely favoring you. Or are you seeing price pressure as well on the back of that?

Bronwyn Brophy O’Connor
23:38 - 24:43

Yeah. Right now it's favoring us because the large clinic chains tend to want to deal with one supplier with a potential backup. They don't want to have to deal and contract with multiple players. I would say maybe a slight bit more price pressure on the genetic side, not so much across the rest of the portfolio. But again, with genetic services, people tend to go with very high-trust players. And that doesn't necessarily mean that they are as cost-sensitive as one would expect. So I would say we're not experiencing high cost pressure in the market. And typically, the larger tenders are something that favors the larger players. Us being one of them. I would say right now, it's a tailwind, not a headwind.

Ulrich Trattner
24:44 - 24:48

Great. Thank you very much, Bronwyn. And I'll get back into the queue.

Bronwyn Brophy O’Connor
24:48 - 24:49

Thank you Ulrich.

Operator
24:53 - 24:57

The next question comes from Jakob Lemke from SEB. Please go ahead.

Jakob Lemke
25:00 - 25:24

Yeah. Hi. A question on APAC. Quite positive development here in the quarter, and you sound a bit more positive on the market growth. But you also highlight that Q1 last year was exceptionally weak. So I guess my question then is, when you look forward, do you see APAC sort of getting back to the prior levels? Low to mid single-digit growth again. Uh, yeah. Looking forward.

Bronwyn Brophy O’Connor
25:25 - 26:47

Yeah. It's a really good question Jakob. It's quite a mixed bag in APAC. So happy to see the growth. But yeah, as you correctly say, Q1 was very low. I think there are some green shoots, but I wouldn't be getting too excited. It's very much regionally based, what we are seeing, and I got this question this morning from Dagens industri is, you know, governments across the world, and we see it here in Sweden are really starting to improve the support for people, not just the IVF costs, but also the cost of raising a child. So I think over the longer horizon, we would have to believe that these measures will start to kick in. But I think I would be cautiously optimistic. Jacob on APAC, you know, it's been turbulent for quite a while. Yes. It's a good quarter and we managed to do particularly well, but I would like to see some sustained quarters of recovery before I could conclusively say that it's returning to the type of numbers that you mentioned. So in summary, it's a bit early to say. Yeah.

Jakob Lemke
26:49 - 27:11

Okay, great. Then, just a follow-up regarding the gross margin, which I believe is strong here in the quarter compared to recent quarters. And as you said, I know it's very mix-sensitive, but I guess if we say that the mix on regions and products are the same, should we expect the same gross margin ahead as well?

Unknown 1
27:12 - 27:13

Thank you.

Pär Ihrskog
27:14 - 28:41

It's a product and market mix where Consumables, which is a high Gross Margin product group, is growing well, and Technologies also shows good growth, with less growth in Genetics, which is the lower Gross Margin product group. I think this mix we have right now is not a one-time mix. I think we can expect a similar mix going forward. Maybe not to that extreme, but leaning towards this mix that we saw now. And we would like to communicate. It's not a coincidence. We are aiming towards growing in the more profitable areas in the more profitable countries. And we are also, as communicated in December, we are leaving some product lines that are not so profitable and leaving some low margin small countries. So these are, of course helping us. And we haven't seen the full effect of this. It started to kick in a little bit in the end of quarter one, but more will come. The full effect we will see in Q2 and onwards. So, that will help us even further on the gross margin.

Jakob Lemke
28:44 - 28:47

Okay. I'll get back to the questions. Thanks.

Operator
28:53 - 28:57

The next question comes from Ludvig Lundgren from Nordea. Please go ahead.

Ludvig Lundgren
28:59 - 29:17

Yes. Hi. And thank you for taking my questions. So I wanted to start out on your current view of the IVF market. You sounded quite optimistic regarding cycle growth coming back to mid-single digits for 26 in the Q4 report. So, has your market view changed in any way since then?

Bronwyn Brophy O’Connor
29:19 - 31:14

Yeah. It's exactly as I said at the start. There are regional differences for sure, but Europe is stable, which is good. That's our largest region. US and North America, as we know, were very rocky last year for all of the reasons that we know. It did start slow, but it's improving, which is good. So, Middle East is a disappointment, but what can we do? You can only control the controllables. APAC, to the point we've just discussed there with Jacob's question. APAC is a mixed bag, but key markets there make a very, a very big difference. So I think it's very hard to say 'if only', but if everything had been normal in the Middle East, I think we would have been back in that sort of range. But of course it isn't. We're all hoping for peace and the sooner that happens the better, but certainly things are a lot more stable than they were last year. And that's, that's good. So yeah, it's been very, very difficult to predict. But we are starting to see, I think the word they use on the other side of the pond is normalcy. We're starting to see more normal cycle levels, which is good. Given the ongoing situation in the Middle East, I don't believe we're back up to mid-single digits. We're not there yet with that situation, but healthier signs in most of the regions, which is good.

Ludvig Lundgren
31:17 - 31:38

Okay. Thanks. Very clear. And then a bit of a follow up on the gross margin side. So you mentioned mix affecting mainly APAC and Americas, but in EMEA, it seems that the mix was somewhat similar to Q1 last year. So, what explains this? I think there was a 2% gross margin increase year over year in EMEA in isolation.

Bronwyn Brophy O’Connor
31:41 - 32:18

Yeah, I can have a go with that part. Technologies and Consumables did very well in Europe in this quarter. Unfortunately, that performance was offset by the situation in the Middle East, but the higher margin parts of the portfolio are performing well in Europe. And as Pat mentioned, Genetic Services is lower margin. So the growth being down doesn't hurt. Yeah, it positively affects the mix. I don't know if you have a better way of explaining it, but.

Pär Ihrskog
32:18 - 32:19

That's it.

Ludvig Lundgren
32:22 - 32:25

Okay, great. Thanks. I'll jump back into the queue.

Unknown 2
32:26 - 32:27

Thank you.

Operator
32:29 - 32:34

The next question comes from Sten Gustafsson from ABG Sundal Collier. Please go ahead.

Sten Gustafsson
32:36 - 33:14

Yes. Good morning. Thank you. I want to ask you about the supply issues you mentioned for one of your competitors. If you could perhaps talk about what kind of products were related here and also how much of the 9% growth you had in the quarter is related to that, if that would be possible to break out.

Bronwyn Brophy O’Connor
33:15 - 34:54

Yeah. So, Sten, thank you for the question. And. So this particular competitor has had supply issues but also recalls and legal challenges. So this has been ongoing for quite a while. So you have a little bit of a compounding impact here, Sten, in terms of, as I stated in previous earnings call, we have captured market share. We've been capturing it for a while. But with that full portfolio play and us becoming much more targeted in terms of the markets where we're playing in, where the ability to leverage the full portfolio and pull through across the rest is leading to share gains in other areas outside of EMEA. And then our consumable growth is well above market growth. The exact split is very, very difficult to quantify. Unfortunately, I'm not being evasive. I just don't have objective data to be able to commit to a number on that. But our Consumables in North America grew 16% in the quarter. That is significantly above the cycle growth in North America this quarter. So, but it has been compounding issues. So it's.

Supply issues, it's recalls, it's distraction. Yeah, it's multiple factors and. Yeah.

Sten Gustafsson
34:56 - 35:30

All right. Thank you very much. And if I may, follow up on the gross margin. Just so I understand correctly. So there are no sort of incremental improvements on your actual products. It's all related to the mix, which we should assume to continue with your ambition to grow in more profitable areas, both from a geographical and product mix.

Pär Ihrskog
35:32 - 36:23

Yeah. We increased prices in our regions last year, which of course still has an impact compared to last year. Then, that is of course contributing. But there is no specific action on a specific product group this quarter. It's more about the mix, the focus on the profitable regions and profitable product lines. That explains the improvement in gross margin. But there is, of course, a price effect there as well, coming from last year's price increases. For example, we increased prices by 6% in the US last year, in the mid year. Last year. I think there is still an impact when you compare to last year.

Bronwyn Brophy O’Connor
36:24 - 37:00

And we have to carry the cost of the tariffs as well. Don't forget that. So we have the tariff piece. Sometimes I think people forget med tech. We have tariffs. Pharma doesn't. So we have to pass those prices on to customers. So we did it quickly, and it helped to insulate us from the tariff effect. So I would say that's not by accident. It's, we took measures and executed on them quickly to protect ourselves.

Sten Gustafsson
37:01 - 37:11

That's very helpful and impressive to see how the gross margin improved here. So thanks for the color on those questions. Thank you.

Unknown 2
37:12 - 37:13

Thank you Stan.

Operator
37:16 - 37:20

The next question comes from Philip Einerson from Redeye. Please go ahead.

Ulrich Trattner
37:22 - 37:23

Okay.

Jakob Lemke
37:23 - 37:48

Hello, everybody. My question is regarding the topic of innovation, which you mentioned in the report, that you're planning to release new products that you're bringing to market. Maybe you could elaborate a little bit on what sort of products these are and also how impactful you expect them to be over, let's say, the coming year or two on the PNL.

Bronwyn Brophy O’Connor
37:49 - 39:49

Yeah. So I would love to tell you that, but I'm not going to tell our competitors who are listening in. What I will tell you is that we have launches coming in all parts of the portfolio. So we have launches coming in Consumables, we have launches coming in Technologies. And we also have launches coming in on the Genetic Services segment. Vitrolife AB has a wonderful history of doing M&A, but I think in-house innovation has been an area for improvement. And we really, really took a strategic decision to double down here a couple of years ago and not throw paint at a wall and try to innovate everything, but to pick the key areas that will move the needle and be impactful for clinics and for patients. And I think what's going to come this year are the results of that R&D prioritization. But I don't know if you're planning to go to Ezra, if you are, hopefully you should see some exciting new things there from the Vitrolife AB group. But it's coming. And then in terms of impact, a couple of the launches, one in particular towards the back end of this year, could be quite meaningful. And equally, I would say, there will be a launch probably coming out back end of this year or early next year, which we also expect to be very meaningful. So I would say two meaningful, impactful ones coming up and others more, I guess what I would call iterative innovation. So yeah, yeah.

Jakob Lemke
39:52 - 40:05

Okay. That's helpful. And with all respect, of course, if you don't want to disclose too much, but maybe you could help us understand if it's more of, let's say, a new product series or if it's more add-ons to existing products and services?

Bronwyn Brophy O’Connor
40:07 - 40:39

Yeah. So it's both. It's some new products. It's other areas where we haven't had an offering before. Others are improvements on what we already have. And then we also have some breakthroughs coming where we would be first to market with a particular technology. So. A sliding scale of exciting things to come. Philip.

Jakob Lemke
40:43 - 40:45

Okay, great. Thank you. Thank you.

Unknown 2
40:46 - 40:46

Yeah.

Operator
40:49 - 40:53

The next question comes from Philip Wiberg from Pareto Securities. Please go ahead.

Philip Wiberg
40:55 - 41:16

Hi. Good morning. I had a question on the Technologies, which was quite strong in Americas. And Q1 is normally on the weaker side. So I'm just trying to get a better sense of the drivers here. So the first, if there were any orders pushed from Q4 to Q1, for instance. And also, what kind of visibility you have going forward now in that area.

Bronwyn Brophy O’Connor
41:17 - 43:02

Very high visibility. We are tracking the funnel on a weekly basis. So we're intensely tracking the funnel for EmbryoScope, for the consumable revenue of EmbryoScope, for the services revenue, and for the pull-through. We have built a commercial excellence engine with best-in-class industry talent. So I can tell you, we are very closely monitoring this. It's not spillover orders that didn't come in in Q4 and came in in Q1. Really what this comes down to is breakthrough in acceptance of EmbryoScope in the clinic chains. That's what it is. And that's been more difficult for us. Historically, Vitrolife AB has been better at selling EmbryoScope to mom-and-pop smaller clinics. But now, with the chains needing to drive efficiency and reduce costs, they are looking for solutions. They really see and appreciate the advantages that EmbryoScope can bring. So while it takes a lot longer to negotiate the purchase of larger numbers of EmbryoScope, the time from lead to close is a lot longer. But when the deals come over the line, they're larger. And that, in the case of Q1, was a big needle mover. But we have very high visibility on the EmbryoScope funnel, utilization, and consumable revenue per EmbryoScope.

Philip Wiberg
43:05 - 43:36

Okay. Thanks. Very happy with that answer. So second one on the just Middle East situation and obviously always very difficult to answer. But the cycle impact, is that mostly about people delaying starting treatment or have you seen any disruptions to your operations as well? And then, I know it's very uncertain, but do you expect any long-standing consequences from this, like we've seen with the insourcing of Genetic Services, or maybe a return to normal once the situation de-escalates? De-escalates.

Unknown 2
43:37 - 43:37

Yeah.

Bronwyn Brophy O’Connor
43:37 - 45:26

So it's mainly, as you rightly point out, Philip, people delaying their IVF cycle. So activity is way down in the clinics. And it's everywhere because sometimes people tend to think it's just Iran, Israel, it's across the Gulf. It's across the Gulf states. So it is that the impact is pretty far reaching. I think this is going to take time to return to normal, you know, because from when a couple. And in the Middle East, it's usually a couple, it's not individuals going. So when a couple starts on the IVF journey, it takes a couple of months before they're ready and before you start actually coming into the clinic for retrievals and transfers and all of that. So, our expectation is it's going to, even if we have peace next week, it's going to take time for the Middle East to recover from this. In terms of disruption to our operations. We do have some disruption to our operations. We have a Genetic Services laboratory in Dubai. So, activities are obviously way down. And in terms of ability to ship to the region, that's also impacted. We have up to now found ways of getting around that. But the entire region is impacted. So volumes are down, cycles are down in the clinics. We've been managing the disruption, but we haven't been unaffected.

Philip Wiberg
45:29 - 45:32

And thank you very much for that.

Bronwyn Brophy O’Connor
45:32 - 45:59

Maybe the other thing, I don't want to sound too negative, but capital sales are way down in the Middle East. So our EMEA region, Technologies did very well in Western Europe, but capital sales are way down in the Middle East, which isn't surprising given the situation. So, we think it's going to take a while for this to recover. Um, yeah.

Philip Wiberg
46:03 - 46:05

Good. I'm happy with that.

Bronwyn Brophy O’Connor
46:05 - 46:07

Okay. Thanks, Philip.

Operator
46:10 - 46:14

The next question comes from Jakob Lemke from Seb. Please go ahead.

Jakob Lemke
46:17 - 46:41

I have some further follow-ups and I'll start with a question on the US. If we look from the market's perspective, I would assume that Q2 last year was the weakest quarter. And I guess also Q3 was a quite weak quarter. So with that in mind, should we see potential for even better growth in that region here in the coming quarters?

Bronwyn Brophy O’Connor
46:43 - 47:38

The start of Q2 wasn't so badly impacted last year. Can we accelerate faster? That's always going to be the goal, right? But we have to say Q1 was very, very strong across the board. The goal is always going to be to maintain that. But I don't think we will see a big bump from the comps in Q2. I think, I think where we would expect it would be more around Q3. Jacob. But it's a good point that you raise in terms of the phasing and the comps from last year. Yeah.

Jakob Lemke
47:39 - 47:51

Okay. That's clear. And then a more general question on Consumables. I'm wondering if there were any large orders or something in the quarter that we should not expect to be in the coming quarters?

Bronwyn Brophy O’Connor
47:56 - 48:26

Were there large orders? Yeah, there were some large orders in South America. So we're starting to perform well in Consumables, in Latam, in South America. But the rest of the regions, it's pretty much steady as she goes. There are no big outliers that I would call out. Yeah.

Jakob Lemke
48:29 - 48:49

Okay. And then I also have a question on the IT projects you're running. I'm wondering if there would be any large investments that make individual quarters deviate, or should we expect the current investment level to be a run rate for the coming quarters?

Pär Ihrskog
48:50 - 49:11

Yeah. I think the current level is what you should expect until further notice. There will be perhaps in the future a need for bigger investments in IT, but for the time being, there are no such decisions. So you can expect the present level going forward.

Jakob Lemke
49:14 - 49:32

Okay, great. And then I'll just ask one final question. And that is another question on the Middle East. If it's possible to, in any way quantify the effect it had in the quarter, let's say, if it had a one percentage point impact to organic growth, for example.

Unknown 3
49:36 - 49:38

I don't think we can quantify that, can we?

Pär Ihrskog
49:41 - 49:44

We don't communicate that. We don't disclose that information.

Unknown 3
49:44 - 49:45

That's what I mean.

Pär Ihrskog
49:48 - 50:05

But we did have, you saw the EMEA. It's a net effect of the Middle East and Western Europe. And as Roman said, strong growth in Western Europe, offset by the negative growth in the Middle East. But we don't disclose the specific impact.

Unknown 3
50:07 - 50:07

Yeah.

Jakob Lemke
50:09 - 50:12

I understand. Thank you very much. That's all for me.

Bronwyn Brophy O’Connor
50:14 - 51:03

Yeah. I don't mean to sound evasive, Jacob, but we don't we don't disclose that. But. But I wouldn't underestimate the magnitude of the drop in the Middle East. It's very significant. It's it's on fumes. Couples are not going forward for IVF in this environment. So it's way down, down enough that in the Vitrolife AB group, it's pulled down the performance of our largest region. So we are severely impacted by this. We are, there's no doubt about it. That's why we're happy with our 5% organic growth in local currencies because we've managed to deliver it well while navigating the Middle East situation. Thanks.

Operator
51:03 - 51:08

The next question comes from Ulrich Trattner from DNB Carnegie. Please go ahead.

Ulrich Trattner
51:10 - 51:36

Thank you very much for taking my follow up question. And one question regarding product launches. And I know that you don't want to give up too much information to your competitors, but if we can just phrase it like this. Your embryo transfer catheter gained 510 K approval mid year last year. Is that a commercial product now or is it still sort of in preparation?

Bronwyn Brophy O’Connor
51:38 - 52:07

Yeah. So you're smart Ulrich. I always underestimate you. That's going to be one of the ones that's coming for sure. And the embryo transfer catheter. . And of course, what's very compelling in our case is we also have embryo glue, right? So we have the catheter. with the embryo glue, which is which is a very nice and compelling value proposition for customers. So that's going to be coming out of the gates.

Ulrich Trattner
52:09 - 52:39

All right. So it's a commercial product launch. Um, great. And a second question would potentially be more addressed to you, Pär. It sounds like you're doing a traditional tail cutting. As you're focusing on higher margin products, higher margin markets to identify low-hanging fruit. How much of the portfolio are you currently reviewing and assessing beyond what's been announced regarding the genetic strategic review?

Pär Ihrskog
52:39 - 53:13

It's an ongoing process. I mean, that what we communicated in December is the lowest hanging fruit. There are more fruits hanging low. So we will continue to do this and we are working. It's a combination of focusing on this, but also developing tools and measures to measure profitability on a customer-level or product-line level and so on. So it's an ongoing process. And we will do more.

Ulrich Trattner
53:13 - 53:24

Is it possible? And is it possible to in any way quantify how much of total or top-line sales would be assessed? Or is it just a review of everything all the time?

Pär Ihrskog
53:26 - 53:39

We don't disclose that information, but we assess everything in all product groups in all regions. Um, yeah.

Ulrich Trattner
53:41 - 54:02

Okay. That's great. Thank you. And for my last question, we're now approaching the one-year mark of the class action lawsuit being filed. And we have seen the dismissal from your competitors here in the last half year. So what can you provide us with an update on the matter?

Bronwyn Brophy O’Connor
54:03 - 55:13

Yeah. How long is a piece of string is unfortunately how these things go. But we see it as a positive sign that there have been other dismissals in this area. And also, the case against Vitrolife AB, I'm not quite sure of the exact legal language, but it wouldn't have been as strong or as compelling as it was against some of the other competitors, but you never quite know. But you know, we're feeling more comfortable around this one in the US. Not to go too technical, but we also have certain clauses in our contracts which provide additional safety for us in these types of instances. So we don't. Let's just put it this way. We don't see any deterioration or need for increased concern around these cases in the United States. In fact, we see it. We see it the opposite way.

Pär Ihrskog
55:13 - 55:25

So it is a very long process as well. And we haven't received any major updates on that in the last couple of months here. So it takes time. But um. Yeah.

Ulrich Trattner
55:27 - 55:41

That's great. And is it possible to in any way quantify how much the lawsuits or legal processes have caused in terms of cost beyond your insurance, etc. ?

Pär Ihrskog
55:42 - 56:06

Yeah. It's not that much. We have not accrued anything when it comes to potential claims, because we don't believe in that. But that will happen. But we have accrued and we have had costs for the legal support. And that is a couple of million SEK. So far.

Ulrich Trattner
56:08 - 56:14

That's great. Thank you for taking my additional questions, and I'll get back into the queue.

Unknown 4
56:15 - 56:16

Thanks, Ulrich.

Operator
56:18 - 56:23

The next question comes from Sten Gustafsson from ABG Sundal Collier. Please go ahead.

Sten Gustafsson
56:25 - 56:48

Yes. Thank you. A very quick follow-up on the Middle East situation. Could you, and I understand you don't want to give us the exact details on how much it has declined, but could you share with us on a normalized level, how much of your sales comes from the Middle East? In a normal year or normal quarter?

Bronwyn Brophy O’Connor
56:53 - 56:58

We don't give the exact percentage, Sten, but I can tell you it's in the single digits.

Sten Gustafsson
57:00 - 57:06

Okay. Thank you. Of global or of EMEA?

Bronwyn Brophy O’Connor
57:06 - 57:09

Globally, in a normal quarter?

Sten Gustafsson
57:10 - 57:10

Yes.

Bronwyn Brophy O’Connor
57:11 - 57:11

Yeah.

Sten Gustafsson
57:11 - 57:12

That makes sense.

Bronwyn Brophy O’Connor
57:12 - 57:13

Okay.

Sten Gustafsson
57:13 - 57:15

Perfect. Thank you.

Operator
57:20 - 57:38

As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. There are no more questions at this time. I hand the conference back to the speakers for any closing comments.

Bronwyn Brophy O’Connor
57:42 - 57:49

Thank you very much for joining us. Over and out from sunny Stockholm. Thank you.

Pär Ihrskog
57:50 - 57:51

Thank you very much.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…